2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-
2020
Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
Aslam A, Gian R, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World Journal Of Hepatology 2020, 12: 738-753. PMID: 33200013, PMCID: PMC7643220, DOI: 10.4254/wjh.v12.i10.738.Peer-Reviewed Original ResearchTreatment response algorithmLI-RADS treatment response algorithmLocoregional therapyLiver Imaging ReportingHepatocellular carcinomaTreatment response assessmentTreatment optionsResponse assessmentData System treatment response algorithmImaging ReportingDifferent locoregional therapiesLiver transplant candidacyHCC treatment responseTransplant candidacyOverall survivalSystemic therapyTumor burdenLeading causeTreatment responseLI-RADSTumor assessmentEconomic burdenClinical practiceTumor progressionTherapyResponse criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
Goldmacher G, Khilnani A, Andtbacka R, Luke J, Hodi F, Marabelle A, Harrington K, Perrone A, Tse A, Madoff D, Schwartz L. Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. Journal Of Clinical Oncology 2020, 38: 3141-3141. DOI: 10.1200/jco.2020.38.15_suppl.3141.Peer-Reviewed Original ResearchLesion responseResponse assessmentIntratumoral immunotherapySolid tumorsTarget lesion responseModification of therapyResponse Evaluation CriteriaRoutine clinical practiceOverall response assessmentUnique treatment strategyInjected lesionsIT drugsRECIST 1.1Immunotherapy trialsNew lesionsTumor burdenMetastatic melanomaTrial protocolClinical trialsInitial progressionTreatment strategiesTherapeutic modalitiesLesion assessmentNadir valuesTreatment evolves
2016
Preoperative portal vein embolization
Li D, Madoff D. Preoperative portal vein embolization. 2016, 176-192. DOI: 10.1017/cbo9781107338555.020.Peer-Reviewed Original ResearchCancer carePreoperative portal vein embolizationPortal vein embolizationComprehensive cancer careRecent clinical dataCancer management strategiesInterventional oncology proceduresInterventional oncology techniquesVein embolizationPalliative benefitTreatment algorithmInvasive image-guided proceduresClinical dataResponse assessmentInterventional radiologistsSide effectsOncology proceduresInterventional oncologyImage-guided proceduresArea of practiceMicrowave ablationTumor ablationIrreversible electroporationImage guidanceTherapy